Back

Ethris secures €30 million EIB financing for respiratory mRNA pipeline

Verifying
  • Ethris, the EIB and DG HERA signed financing for respiratory mRNA development.
  • The €30 million agreement supports ETH47, ETH52 and ETH53 programs.
  • ETH47 is in a Phase 2a asthma trial and is planned for COPD evaluation.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.